tetano
Editor, Senior Moderator
J Med Virol
. 2021 Feb 16.
doi: 10.1002/jmv.26878. Online ahead of print.
Anti-Spike S1 Receptor-Binding Domain Antibodies against SARS-CoV-2 Persist Several Months after Infection Regardless of Disease Severity
Bavaro Davide Fiore[SUP] 1 [/SUP], Laghetti Paola[SUP] 1 [/SUP], Milano Eugenio[SUP] 1 [/SUP], Brindicci Gaetano[SUP] 1 [/SUP], Volpe Anna[SUP] 1 [/SUP], Lagioia Antonella[SUP] 1 [/SUP], Saracino Annalisa[SUP] 1 [/SUP], Monno Laura[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Data regarding the immunological memory and long-time kinetics of IgG against viral Nucleoprotein (NP) and Spike Protein S1 Receptor-Binding Domain (S1RBD) of Severe-Acute-Respiratory-Syndrome associated Coronavirus 2 (SARS-CoV-2) are lacking.
Methods: All consecutive COVID-19 patients, admitted to our Clinic between March 1st, 2020 and May 1st, 2020, who were tested at hospital admission for anti-S1RBD and anti-NP IgG were enrolled. Serum samples were tested for anti SARS-CoV-2 antibodies with the use of two commercially available ELISA assays. Results are expressed as Optical Density measurements at 450nm (OD[SUB]450[/SUB] ).
Results: Overall, 111 patients were included; median (q1-q3) age was 57 (49 - 73) years, 59 (53%) males. According to disease severity, 31 (28%), 47 (42%) and 33 (30%) patients were considered affected by mild/moderate, severe, and critical SARS-CoV-2 infection, respectively. During hospitalization, patients with critical disease showed a higher peak value of both anti-NP (median OD450: 3.66 vs 3.06 vs 3.00 respectively, p=0.043) and anti-S1RBD IgG (median OD450: 2.33 vs 1.6 vs 0.91 respectively, p<0.001). By testing 48 subjects ≥6 months from discharge, a significant decrease of anti-NP IgG was observed (r: -0.5838; p<0.0001), while anti-S1RBD IgG showed only a modest reduction (r: -0.1507; p=0.0647). Accordingly, 10 (21%) and 2 (4%) patients had a negative serological status for anti-NP and anti-S1RBD IgG, respectively; no association with clinical severity was found.
Conclusions: Immunoglobulins against SARS-CoV-2 persisted several months after discharge, regardless of disease severity, suggesting that vaccination could be a valid strategy to fight the pandemic. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; Serology; anti-S1RBD.
. 2021 Feb 16.
doi: 10.1002/jmv.26878. Online ahead of print.
Anti-Spike S1 Receptor-Binding Domain Antibodies against SARS-CoV-2 Persist Several Months after Infection Regardless of Disease Severity
Bavaro Davide Fiore[SUP] 1 [/SUP], Laghetti Paola[SUP] 1 [/SUP], Milano Eugenio[SUP] 1 [/SUP], Brindicci Gaetano[SUP] 1 [/SUP], Volpe Anna[SUP] 1 [/SUP], Lagioia Antonella[SUP] 1 [/SUP], Saracino Annalisa[SUP] 1 [/SUP], Monno Laura[SUP] 1 [/SUP]
Affiliations
- PMID: 33590900
- DOI: 10.1002/jmv.26878
Abstract
Introduction: Data regarding the immunological memory and long-time kinetics of IgG against viral Nucleoprotein (NP) and Spike Protein S1 Receptor-Binding Domain (S1RBD) of Severe-Acute-Respiratory-Syndrome associated Coronavirus 2 (SARS-CoV-2) are lacking.
Methods: All consecutive COVID-19 patients, admitted to our Clinic between March 1st, 2020 and May 1st, 2020, who were tested at hospital admission for anti-S1RBD and anti-NP IgG were enrolled. Serum samples were tested for anti SARS-CoV-2 antibodies with the use of two commercially available ELISA assays. Results are expressed as Optical Density measurements at 450nm (OD[SUB]450[/SUB] ).
Results: Overall, 111 patients were included; median (q1-q3) age was 57 (49 - 73) years, 59 (53%) males. According to disease severity, 31 (28%), 47 (42%) and 33 (30%) patients were considered affected by mild/moderate, severe, and critical SARS-CoV-2 infection, respectively. During hospitalization, patients with critical disease showed a higher peak value of both anti-NP (median OD450: 3.66 vs 3.06 vs 3.00 respectively, p=0.043) and anti-S1RBD IgG (median OD450: 2.33 vs 1.6 vs 0.91 respectively, p<0.001). By testing 48 subjects ≥6 months from discharge, a significant decrease of anti-NP IgG was observed (r: -0.5838; p<0.0001), while anti-S1RBD IgG showed only a modest reduction (r: -0.1507; p=0.0647). Accordingly, 10 (21%) and 2 (4%) patients had a negative serological status for anti-NP and anti-S1RBD IgG, respectively; no association with clinical severity was found.
Conclusions: Immunoglobulins against SARS-CoV-2 persisted several months after discharge, regardless of disease severity, suggesting that vaccination could be a valid strategy to fight the pandemic. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; Serology; anti-S1RBD.